{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=16", "query": { "intervention": "Placebo- matched", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 7052, "total_pages": 706, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+matched&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T21:09:12.618Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00153803", "title": "Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Non-small Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "Erlotinib (tarceva)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 245, "start_date": "2005-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00153803" }, { "nct_id": "NCT01870778", "title": "Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Heart Failure" ], "interventions": [ { "name": "RLX030", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6600, "start_date": "2013-10-02", "completion_date": "2017-02-01", "has_results": true, "last_update_posted_date": "2018-03-30", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 105, "location_summary": "Huntsville, Alabama • Montgomery, Alabama • Tucson, Arizona + 76 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01870778" }, { "nct_id": "NCT03389555", "title": "Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Sepsis", "Septic Shock", "Metabolic Disturbance" ], "interventions": [ { "name": "vitamin C, vitamin B1, hydrocortisone", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 205, "start_date": "2018-02-09", "completion_date": "2020-02-28", "has_results": true, "last_update_posted_date": "2021-02-16", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Boston, Massachusetts • Cambridge, Massachusetts + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cambridge", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03389555" }, { "nct_id": "NCT02509117", "title": "First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "PF-06751979 single ascending dose", "type": "DRUG" }, { "name": "Placebo single dose", "type": "DRUG" }, { "name": "PF-06751979 multiple ascending dose", "type": "DRUG" }, { "name": "Placebo multiple dose", "type": "DRUG" }, { "name": "PF-06751979 multiple dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 55, "start_date": "2015-07", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2018-11-01", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 2, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02509117" }, { "nct_id": "NCT00904462", "title": "Pilot Study of Lidocaine 5% Patch Versus Placebo in Patients With Osteoarthritis Pain of the Knee", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteoarthritis, Knee" ], "interventions": [ { "name": "Lidoderm", "type": "DRUG" }, { "name": "Placebo patch", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2004-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-02-10", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Hueytown, Alabama • Tallassee, Alabama + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hueytown", "state": "Alabama" }, { "city": "Tallassee", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00904462" }, { "nct_id": "NCT02163915", "title": "Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Attention-Deficit/Hyperactivity Disorder" ], "interventions": [ { "name": "TAK-137", "type": "DRUG" }, { "name": "TAK-137 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 47, "start_date": "2014-06", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2016-07-11", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 1, "location_summary": "Marlton, New York", "locations": [ { "city": "Marlton", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02163915" }, { "nct_id": "NCT04456517", "title": "Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Crohn's Disease", "Inflammatory Bowel Disease" ], "interventions": [ { "name": "Ranolazine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2022-10-18", "completion_date": "2024-04-11", "has_results": true, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04456517" }, { "nct_id": "NCT05890950", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity", "Type 2 Diabetes Mellitus in Obese" ], "interventions": [ { "name": "K-757 and K-833", "type": "DRUG" }, { "name": "Matching placebo to K-757 and K-833", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TriGemX Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2023-03-13", "completion_date": "2023-07-12", "has_results": false, "last_update_posted_date": "2023-10-05", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 1, "location_summary": "Newark, Delaware", "locations": [ { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT05890950" }, { "nct_id": "NCT04706091", "title": "Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Restless Legs Syndrome", "Insomnia", "Sleep Disorder" ], "interventions": [ { "name": "Suvorexant", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "25 Years to 85 Years" }, "enrollment_count": 46, "start_date": "2021-08-12", "completion_date": "2023-10-20", "has_results": true, "last_update_posted_date": "2024-01-16", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04706091" }, { "nct_id": "NCT00973024", "title": "A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Back Pain", "Low Back Pain, Recurrent" ], "interventions": [ { "name": "JNJ-42160443 3 mg", "type": "DRUG" }, { "name": "JNJ-42160443 1 mg", "type": "DRUG" }, { "name": "JNJ-42160443 6 mg/3mg", "type": "DRUG" }, { "name": "JNJ-42160443 10 mg", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 389, "start_date": "2009-09", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2016-06-06", "last_synced_at": "2026-11-10T21:09:12.618Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Pismo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00973024" } ] }